Why spinal cord stimulation, rTMS, and neuropathic pain assessments demand indication-specific comparators, credible long-term outcomes, and a pathway from clinical evidence to funding. Spain and France are scrutinising neuromodulation from …
A practical evidence and health-economic framework for measuring pathway change, released clinical capacity, performance-based payment and value capture. 29 September 2026 1. The economic question has been framed too narrowly …
Why Static Cost-Effectiveness Models Fall Short A lifecycle approach to evidence, health economics, AI, implementation and market access 29 September 2026 The economic value of a digital technology is not …
On 23 July 2026, France’s Haute Autorité de Santé announced the creation of MiMED — Mission Méthodes, Europe, Données. MiMED is an expansion of the Cellule de coordination des données …
What reconstructed patient-level survival data can and cannot tell us Odelle Technology | September 2026 A Kaplan-Meier curve is not merely a picture. It contains enough structured information that, under …
What metastatic pancreatic cancer reveals about patient choice, real-world evidence and the denominator Two contemporary datasets appear to describe radically different treatment uptake in metastatic pancreatic cancer: 72% untreated in …
What Spain’s new HTA system means for biotech reimbursement after European Joint Clinical Assessment Europe has harmonised part of the clinical assessment. It has not harmonised reimbursement. Spain’s Real Decreto …
France has not launched a new early-access scheme. It has changed the operating rules of an established route that can place innovative medicines into funded clinical use before conventional reimbursement …
Why Britain’s subscription model is trying to make antimicrobial stewardship compatible with pharmaceutical innovatio There is something economically strange about a good antibiotic. We want it to exist. We may …
A practical, evidence-led guide to DiGA, G-BA methods assessment, §137e evidence generation, hospital NUB funding, §137h high-risk device assessment and the emerging problem of undocumented AI inside “usual care”. Editorial …